Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by First National Bank of Omaha

First National Bank of Omaha cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,987 shares of the specialty pharmaceutical company’s stock after selling 2,505 shares during the quarter. First National Bank of Omaha’s holdings in Jazz Pharmaceuticals were worth $3,341,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. LSV Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after purchasing an additional 99,705 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Baupost Group LLC MA grew its holdings in Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after buying an additional 398,549 shares in the last quarter. Finally, Swedbank AB bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $106,936,000. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of recent analyst reports. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,753 shares of company stock worth $816,289. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $122.59 on Monday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The stock has a fifty day moving average price of $116.18 and a two-hundred day moving average price of $111.63. The firm has a market cap of $7.41 billion, a P/E ratio of 17.27, a PEG ratio of 1.04 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.